A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

MSD’s monoclonal antibody, indicated for 15 types of cancer, smashed industry records with sales of $27.3 billion in 2024, ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

Recent market volatility notwithstanding, equities generally deliver solid returns over long periods, like a decade. The key ...

Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda can cut the time spent in ...

Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s ...

Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and ...

Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous (under the skin or ...

When topline phase III data was released in November, hinting at the potential of success, Jefferies analyst Akash Tiwari ...

The health sector faces challenges as Novo Nordisk's sales projections dim, Johnson & Johnson's unit faces hefty fines, and ...